P-CD19CD20-ALLO1 is under clinical development by F. Hoffmann-La Roche and currently in Phase I for Refractory Chronic Lymphocytic Leukemia (CLL). According to GlobalData, Phase I drugs for Refractory Chronic Lymphocytic Leukemia (CLL) have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how P-CD19CD20-ALLO1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
P-CD19CD20-ALLO1 overview
P-CD19CD20-ALL01 is under development for the treatment of relapsed or refractory B-cell malignacies like diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone b-cell lymphoma, primary mediastinal b-cell lymphoma, chronic lymphocytic leukemia and also autoimmune diseases. It comprises allogeneic stem memory T cells (Tscm), genetically engineered to express chimeric antigen receptors (CARs). It acts by targeting the cells expressing CD19 and CD20. The therapeutic candidate is being developed based on Piggybac DNA modification system and CAS Clover gene-editing technology. It is administered through intravenous route.
See Also:
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company that develops drugs and diagnostics to treat major diseases. It provides medicines for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers, and pharmacists. Together with its subsidiaries and partners, the company has operations in various countries. Roche is headquartered in Basel, Switzerland.
For a complete picture of P-CD19CD20-ALLO1’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
